medigraphic.com
ISSN 0326-3428 (Print)
Órgano de difusión científica de la Asociación Nefrológica de Buenos Aires

2020, Number 4

<< Back Next >>

Rev Nefrol Dial Traspl 2020; 40 (4)

Case Report of Rapidly Progressive Glomerulonephritis Due to Anti-Glomerular Basement Membrane Antibodies

Zoppi ME, Marovelli L, Paz MM, Agost CC, Díaz FF

Language: Spanish
References: 10
Page: 325-329.
PDF size: 233.73 Kb.


ABSTRACT

Once again in internal medicine we cannot do a diagnosis without invasive methods. Daily advances in the finding of new paraclinical tools do not allow the replacement of certain methods such as pathological anatomy. The case presented is a sample of this. This is a 27-yearold woman with a history of Hashimoto’s thyroiditis who consults for presenting severe impairment of kidney function associated with oligoanuria. We performed a review of the treatment of the rapidly progressive glomerulonephritis for serologically negative anti-GBM antibodies.


REFERENCES

  1. Fogo AB, Kashgarian M. Diagnostic atlas of renalpathology. 3rd ed. Philadelphia, PA: Elsevier, 2017, pp. 246-77.

  2. Berden AE, Ferrario F, Hagen EC, Jayne DR, JennetteJC, Joh K, et al. Histopathologic classificationof ANCA-associated glomerulonephritis. J AmSoc Nephrol. 2010;21(10):1628-36. doi: 10.1681/ASN.2010050477.

  3. Sinico RA, Radice A, Corace C, Sabadini E, BolliniB. Anti-glomerular basement membrane antibodies inthe diagnosis of Goodpasture syndrome: a comparisonof different assays. Nephrol Dial Transplant.2006;21(2):397-401. doi: 10.1093/ndt/gfi230.

  4. Chen M, Kallenberg CG, Zhao MH. ANCAnegativepauci-immune crescentic glomerulonephritis.Nat Rev Nephrol. 2009;5(6):313-8. doi: 10.1038/nrneph.2009.67.

  5. Turner AN, Rees AJ. Antiglomerular basementmembrane disease. En: Cameron JS, Davison AM,Grunfeld JP, et al. Oxford textbook of nephrology. 3rd ed.Oxford: Oxford University Press, 2005, pp. 579-600.

  6. Fernandes R, Freitas S, Cunha P, Alves G, Cotter J.Goodpasture’s syndrome with absence of circulatinganti-glomerular basement membrane antibodies: acase report. J Med Case Rep. 2016;10:205. doi: 10.1186/s13256-016-0984-6.

  7. Nishibata Y, Masuda S, Nakazawa D, Tanaka S,Tomaru U, Nergui M, et al. Epitope recognized byanti-glomerular basement membrane (GBM) antibodyin a patient with repeated relapse of anti-GBM disease.Exp Mol Pathol. 2019;107:165-70. doi: 10.1016/j.yexmp.2019.02.005.

  8. Lemahieu W, Ombelet S, Lerut E, Jamar S, SprangersB. Reversal of dialysis-dependent anti-glomerularbasement membrane disease using plasma exchange,glucocorticosteroids, and rituximab. Kidney Int Rep.2018;3(5):1229-32. doi: 10.1016/j.ekir.2018.04.015.

  9. Touzot M, Poisson J, Faguer S, Ribes D, Cohen P,Geffray L, et al. Rituximab in anti-GBM disease:A retrospective study of 8 patients. J Autoimmun.2015;60:74-9. doi: 10.1016/j.jaut.2015.04.003.

  10. Geetha D, Specks U, Stone JH, Merkel PA, Seo P,Spiera R, et al. Rituximab for ANCA-AssociatedVasculitis Immune Tolerance Network ResearchGroup. Rituximab versus cyclophosphamide forANCA-associated vasculitis with renal involvement.J Am Soc Nephrol. 2015;26(4):976-85. doi: 10.1681/ASN.2014010046.




2020     |     www.medigraphic.com